Myokardia Company Profile (NASDAQ:MYOK)

About Myokardia (NASDAQ:MYOK)

Myokardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MYOK
  • CUSIP: N/A
  • Web:
  • Market Cap: $437.24 million
  • Outstanding Shares: 31,455,000
Average Prices:
  • 50 Day Moving Avg: $13.57
  • 200 Day Moving Avg: $13.04
  • 52 Week Range: $10.55 - $22.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.86
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $41.27 million
  • Price / Sales: 10.37
  • Book Value: $4.30 per share
  • Price / Book: 3.16
  • EBIDTA: ($15,460,000.00)
  • Net Margins: -205.28%
  • Return on Equity: -33.01%
  • Return on Assets: -24.01%
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
  • Average Volume: 137,319 shs.
  • Beta: 6.02
  • Short Ratio: 8.98
Frequently Asked Questions for Myokardia (NASDAQ:MYOK)

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.01. The firm earned $5.60 million during the quarter, compared to the consensus estimate of $7 million. Myokardia had a negative return on equity of 33.01% and a negative net margin of 205.28%. The firm's revenue for the quarter was up 55.6% on a year-over-year basis. View Myokardia's Earnings History.

Where is Myokardia's stock going? Where will Myokardia's stock price be in 2017?

4 brokerages have issued 1 year price targets for Myokardia's stock. Their predictions range from $24.00 to $32.00. On average, they anticipate Myokardia's share price to reach $28.00 in the next twelve months. View Analyst Ratings for Myokardia.

Who are some of Myokardia's key competitors?

Who are Myokardia's key executives?

Myokardia's management team includes the folowing people:

  • Tassos Anastasios Gianakakos, President, Chief Executive Officer, Director
  • June Lee M.D., Chief Operating Officer
  • Jake Bauer, Senior Vice President - Finance and Corporate Development
  • Joseph Lambing Ph.D., Senior Vice President - Nonclinical and Pharmaceutical Development
  • Robert Scott McDowell Ph.D., Senior Vice President - Drug Discovery
  • Marc Semigran M.D., Chief Medical Officer
  • Mark L. Perry J.D., Interim Non-Executive Chairman of the Board, Lead Independent Director
  • Kevin P. Starr, Director
  • Sunil Agarwal M.D., Independent Director
  • Mary B. Cranston, Independent Director

How do I buy Myokardia stock?

Shares of Myokardia can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myokardia's stock price today?

One share of Myokardia stock can currently be purchased for approximately $13.60.

MarketBeat Community Rating for Myokardia (NASDAQ MYOK)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Myokardia (NASDAQ:MYOK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.00 (105.88% upside)

Analysts' Ratings History for Myokardia (NASDAQ:MYOK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017BMO Capital MarketsReiterated RatingOutperform$32.00LowView Rating Details
3/13/2017WedbushReiterated RatingOutperform$24.00HighView Rating Details
11/8/2016Cowen and CompanyReiterated RatingBuy$28.00N/AView Rating Details
9/22/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuy$16.00 -> $20.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Myokardia (NASDAQ:MYOK)
Earnings by Quarter for Myokardia (NASDAQ:MYOK)
Earnings History by Quarter for Myokardia (NASDAQ MYOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Myokardia (NASDAQ:MYOK)
2017 EPS Consensus Estimate: ($1.50)
2018 EPS Consensus Estimate: ($1.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.39)($0.39)($0.39)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.42)($0.42)($0.42)
Q1 20181($0.39)($0.39)($0.39)
Q2 20181($0.40)($0.40)($0.40)
Q3 20181($0.41)($0.41)($0.41)
Q4 20181($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)


Dividend History for Myokardia (NASDAQ:MYOK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Myokardia (NASDAQ:MYOK)
Insider Ownership Percentage: 46.10%
Institutional Ownership Percentage: 47.72%
Insider Trades by Quarter for Myokardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)
Insider Trades by Quarter for Myokardia (NASDAQ:MYOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.00View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.00View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Myokardia (NASDAQ:MYOK)
Latest Headlines for Myokardia (NASDAQ:MYOK)
DateHeadline logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 21, 2017 - July 22 at 6:45 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Given Consensus Rating of "Buy" by Brokerages - July 18 at 6:56 PM logoETFs with exposure to MyoKardia, Inc. : July 14, 2017 - July 15 at 6:45 AM logoMyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : July 12, 2017 - July 13 at 7:06 AM logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 11, 2017 - July 12 at 5:47 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Upgraded at TheStreet - July 11 at 11:54 AM logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : June 28, 2017 - June 28 at 11:38 AM logoMyoKardia, Inc. (MYOK) Given Average Recommendation of "Buy" by Analysts - June 23 at 5:08 PM logoETFs with exposure to MyoKardia, Inc. : June 15, 2017 - June 16 at 7:57 AM logoMyoKardia, Inc. :MYOK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 - June 9 at 6:57 PM logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : June 2, 2017 - June 2 at 8:07 PM logoMyokardia Inc (MYOK) Given Consensus Recommendation of "Buy" by Brokerages - May 29 at 4:56 PM logoMyokardia Inc (MYOK) Downgraded by TheStreet to "D+" - May 23 at 5:34 PM logoMyokardia Inc (MYOK) Stock Rating Lowered by Zacks Investment Research - May 14 at 9:12 AM logoMyokardia Inc Expected to Earn Q2 2017 Earnings of ($0.39) Per Share (MYOK) - May 12 at 10:24 AM logoMyokardia Inc (MYOK) Earns "Outperform" Rating from BMO Capital Markets - May 10 at 4:02 PM logoMyoKardia reports 1Q loss - May 10 at 12:12 PM logoMyokardia Inc (MYOK) Announces Earnings Results, Misses Estimates By $0.06 EPS - May 9 at 9:22 PM logoInvestor Network: MyoKardia, Inc. to Host Earnings Call - May 9 at 6:21 PM logoMyoKardia Reports First Quarter 2017 Financial Results and Operational Progress - May 9 at 6:21 PM logoMyokardia (MYOK) Given Coverage Optimism Score of 0.14 - May 8 at 11:44 PM logoMyokardia Inc (MYOK) Receives $25.00 Consensus Price Target from Brokerages - May 6 at 12:50 AM logoMyokardia (MYOK) Receives Daily Coverage Optimism Score of -0.09 - May 3 at 9:49 AM logoMyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017 - May 2 at 7:24 PM logoMyokardia Inc (MYOK) Given Average Rating of "Buy" by Brokerages - May 2 at 4:24 PM logoMyokardia (MYOK) Getting Somewhat Positive News Coverage, Report Finds - April 28 at 12:25 AM logoHow a new biotech model looks to disrupt a fatal genetic disease - April 27 at 7:14 PM logoMyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : April 26, 2017 - April 26 at 6:34 PM logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : April 25, 2017 - April 25 at 6:00 PM logoMyokardia (MYOK) Given Daily News Impact Rating of -0.22 - April 23 at 11:02 AM logoShort Interest in Myokardia Inc (MYOK) Drops By 17.7% - April 20 at 5:56 PM logoMyokardia (MYOK) Getting Somewhat Favorable Press Coverage, Report Finds - April 19 at 12:59 PM logoMyoKardia Appoints David Meeker, M.D., to Board of Directors - April 18 at 10:14 AM logoETFs with exposure to MyoKardia, Inc. : April 13, 2017 - April 13 at 6:27 PM logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : April 6, 2017 - April 7 at 11:24 AM logoMyokardia Inc (MYOK) Receives Consensus Recommendation of "Buy" from Analysts - April 5 at 3:40 PM logoInsider Selling: Myokardia Inc (MYOK) Insider Sells 667 Shares of Stock - March 22 at 11:07 PM logoMyokardia Inc (MYOK) CEO Anastasios Gianakakos Sells 1,412 Shares - March 22 at 10:49 PM logoBRIEF-Myokardia appoints Kim Popovits, Wendy Yarno to board - March 18 at 9:09 AM logoMyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors - March 17 at 8:38 AM logoMyokardia Inc (MYOK) to Post Q1 2017 Earnings of ($0.29) Per Share, Wedbush Forecasts - March 15 at 10:11 AM logoBRIEF-Myokardia Q4 net income $14.3 mln - March 13 at 6:26 PM logoMyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress - March 13 at 10:13 AM logoMyoKardia reports 4Q loss - March 13 at 10:13 AM logoMYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 6 at 8:16 AM logo7 Stocks Trending With Monster Volume - March 2 at 9:20 AM logoMyoKardia to Present at Cowen and Company 37th Annual Health Care Conference - February 28 at 10:18 AM logoBRIEF-Myokardia says first subjects dosed in cardiomyopathy drug study - February 3 at 7:28 PM logoFirst Subjects Dosed in Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491 - February 2 at 7:35 PM logoMyoKardia (MYOK) Appoints June Lee as COO - February 2 at 12:47 AM



Myokardia (MYOK) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff